Literature DB >> 24795140

Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?

Eric R Lutz1, Elizabeth M Jaffee2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24795140      PMCID： PMC4343532          DOI： 10.1158/2326-6066.CIR-14-0041

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN： 2326-6066            Impact factor:   11.151


× No keyword cloud information.
  18 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

Review 2.  Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus.

Authors:  Cornelis J M Melief
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 3.  Immune resistance orchestrated by the tumor microenvironment.

Authors:  Thomas F Gajewski; Yuru Meng; Christian Blank; Ian Brown; Aalok Kacha; Justin Kline; Helena Harlin
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

4.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.

Authors:  K C Parker; M A Bednarek; J E Coligan
Journal:  J Immunol       Date:  1994-01-01       Impact factor: 5.422

5.  A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.

Authors:  Eric Lutz; Charles J Yeo; Keith D Lillemoe; Barbara Biedrzycki; Barry Kobrin; Joseph Herman; Elizabeth Sugar; Steven Piantadosi; John L Cameron; Sara Solt; Beth Onners; Irena Tartakovsky; Miri Choi; Rajni Sharma; Peter B Illei; Ralph H Hruban; Ross A Abrams; Dung Le; Elizabeth Jaffee; Dan Laheru
Journal:  Ann Surg       Date:  2011-02       Impact factor: 12.969

6.  Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity.

Authors:  Natalie A Bowerman; Terence S Crofts; Lukasz Chlewicki; Priscilla Do; Brian M Baker; K Christopher Garcia; David M Kranz
Journal:  Mol Immunol       Date:  2009-09       Impact factor: 4.407

Review 7.  HLA-binding properties of tumor neoepitopes in humans.

Authors:  Edward F Fritsch; Mohini Rajasagi; Patrick A Ott; Vladimir Brusic; Nir Hacohen; Catherine J Wu
Journal:  Cancer Immunol Res       Date:  2014-03-03       Impact factor: 11.151

8.  Epitope landscape in breast and colorectal cancer.

Authors:  Neil H Segal; D Williams Parsons; Karl S Peggs; Victor Velculescu; Ken W Kinzler; Bert Vogelstein; James P Allison
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

Review 9.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Authors:  Amy Morck Thomas; Lynn M Santarsiero; Eric R Lutz; Todd D Armstrong; Yi-Cheng Chen; Lan-Qing Huang; Daniel A Laheru; Michael Goggins; Ralph H Hruban; Elizabeth M Jaffee
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307
View more
  2 in total

1.  Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma.

Authors:  Ombretta Melaiu; Marco Chierici; Valeria Lucarini; Giuseppe Jurman; Libenzio Adrian Conti; Rita De Vito; Renata Boldrini; Loredana Cifaldi; Aurora Castellano; Cesare Furlanello; Vincenzo Barnaba; Franco Locatelli; Doriana Fruci
Journal:  Nat Commun       Date:  2020-11-25       Impact factor: 14.919

Review 2.  Cancer vaccine: learning lessons from immune checkpoint inhibitors.

Authors:  ZhenLong Ye; Qiming Qian; HuaJun Jin; QiJun Qian
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.